HONG KONG – South Korea's Samsung Bioepis Co. Ltd. has taken another step forward in its push to market biosimilars globally having received positive feedback from the EMA for its biosimilar to Remicade (infliximab, Janssen Biotech Inc.). The company is now expecting an approval soon.
HONG KONG – South Korea's Samsung Bioepis Co. Ltd. has taken another step forward in its push to market biosimilars globally having received positive feedback from the EMA for its biosimilar to Remicade (infliximab, Janssen Biotech Inc.). The company is now expecting an approval soon.
HONG KONG — Leading investment bank Goldman Sachs Group Inc. has injected $37 million into Chinese medical device company Venus Medtech (Hangzhou) Inc. after the creation of the first specialized cardiac valve research institute in China.
SINGAPORE – Better quality filings, more reliable manufacturing and much-improved regulatory environments have rendered mute many of the longstanding concerns associated with the biopharma industry in Asia.
SINGAPORE – Across much of Asia, and in China in particular, the responsibility of fighting for the rights of rare disease patients mostly falls on the shoulders of patient themselves. By talking with the government and industry, patient groups are pushing for more effective drug development and orphan drug discovery policies. Unfortunately, once disease conditions and cultural elements are taken into account, those groups may have significant challenges ahead.
SINGAPORE – Across much of Asia, and in China in particular, the responsibility of fighting for the rights of rare disease patients mostly falls on the shoulders of patient themselves.
SINGAPORE – Better quality filings, more reliable manufacturing and much-improved regulatory environments have rendered mute many of the longstanding concerns associated with the biopharma industry in Asia.
